David A. Siegel Humacyte, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q3 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Humacyte, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 188,400 shares of HUMA stock, worth $830,844. This represents 0.0% of its overall portfolio holdings.
Number of Shares
188,400
Previous 264,300
28.72%
Holding current value
$830,844
Previous $1.27 Million
19.24%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding HUMA
# of Institutions
149Shares Held
35.1MCall Options Held
279KPut Options Held
607K-
Black Rock Inc. New York, NY7.14MShares$31.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.06MShares$22.3 Million0.0% of portfolio
-
State Street Corp Boston, MA4.76MShares$21 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.04MShares$9 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.27MShares$5.59 Million0.0% of portfolio
About Humacyte, Inc.
- Ticker HUMA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,007,000
- Market Cap $454M
- Description
- Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular ...